Literature DB >> 11790983

Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence.

Sam Thiagalingam1, Rebecca L Foy, Kuang-hung Cheng, Hyunjoo J Lee, Arunthathi Thiagalingam, Jose F Ponte.   

Abstract

High frequency of chromosomal deletions elicited as losses of heterozygosity is a hallmark of genomic instability in cancer. Functional losses of tumor suppressor genes caused by loss of heterozygosity at defined regions during clonal selection for growth advantage define the minimally lost regions as their likely locations on chromosomes. Loss of heterozygosity is elicited at the molecular or cytogenetic level as a deletion, a gene conversion, single or double homologous and nonhomologous mitotic recombinations, a translocation, chromosome breakage and loss, chromosomal fusion or telomeric end-to-end fusions, or whole chromosome loss with or without accompanying duplication of the retained chromosome. Because of the high level of specificity, loss of heterozygosity has recently become invaluable as a marker for diagnosis and prognosis of cancer. The molecular defects for the occurrence of loss of heterozygosity are derived from disabled caretaker genes, which protect the integrity of DNA, or chromosome segregator genes, which mediate faithful chromosome disjunction.

Entities:  

Mesh:

Year:  2002        PMID: 11790983     DOI: 10.1097/00001622-200201000-00012

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  32 in total

1.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.

Authors:  Sarina Sulong
Journal:  Malays J Med Sci       Date:  2010-07

3.  Aneuploid neurons are functionally active and integrated into brain circuitry.

Authors:  M A Kingsbury; B Friedman; M J McConnell; S K Rehen; A H Yang; D Kaushal; J Chun
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-18       Impact factor: 11.205

4.  Differences in genomic instability between intestinal- and diffuse-type gastric cancer.

Authors:  Matti Vauhkonen; Hanna Vauhkonen; Antti Sajantila; Pentti Sipponen
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 5.  Epigenetic memory in development and disease: Unraveling the mechanism.

Authors:  Sam Thiagalingam
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-01-23       Impact factor: 10.680

6.  Loss of heterozygosity in multistage carcinogenesis of esophageal carcinoma at high-incidence area in Henan Province, China.

Authors:  Ji-Ye An; Zong-Min Fan; Shan-Shan Gao; Ze-Hao Zhuang; Yan-Ru Qin; Ji-Lin Li; Xin He; George-Sai-Wah Tsao; Li-Dong Wang
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

7.  Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer.

Authors:  Barbara Domazet; Gregory T Maclennan; Antonio Lopez-Beltran; Rodolfo Montironi; Liang Cheng
Journal:  Int J Clin Exp Pathol       Date:  2008-03-15

8.  Mosaicism by somatic non-functional mutations: one cell lineage at a time.

Authors:  Willy Albert Flegel
Journal:  Haematologica       Date:  2019-03       Impact factor: 9.941

9.  Alterations of microsatellite loci GSN and D18S51 in urinary bladder cancer.

Authors:  S Saidi; Z Popov; S Stavridis; S Panov
Journal:  Hippokratia       Date:  2015 Jul-Sep       Impact factor: 0.471

10.  A new method to detect loss of heterozygosity using cohort heterozygosity comparisons.

Authors:  Michael R Green; Paul Jardine; Peter Wood; Jeremy Wellwood; Rod A Lea; Paula Marlton; Lyn R Griffiths
Journal:  BMC Cancer       Date:  2010-05-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.